Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

McCormick Place

18 jun 2017 1:00 p.m. - 18 jun 2017 4:30 p.m.

2301 South Martin Luther King Jr. Drive, Gate 4, Chicago, IL 60616

#34: Implementing a Risk-Based Monitoring Solution: Understanding the Basics of a Sustainable Model

Instructors

Mary  Arnould, BSN, MSN

Mary Arnould, BSN, MSN

Director, Clinical Science Operations, Astellas, United States

Mary Arnould is Director, Center of Excellence & RBM Lead at Astellas Pharma and has been at Astellas over 3 years. She has over 25 years of clinical operations and site monitoring management experience, focusing on RBM implementation since 2014. Mary is currently leading RBM implementation and the Clinical Compliance Team at Astellas. Her vast clinical operations and monitoring experience has allowed her to help evolve the risk-based approach implemented at Astellas exploring ways to evaluate effectiveness, promote adaptability, leverage technology, and enhance processes to meet the challenges presented by the current pandemic. Mary is an active member in the TransCelerate RBM work stream.

Cecilie  Freddie Lange

Cecilie Freddie Lange

RBM Specialist, Novo Nordisk A/S, Denmark

Stuart  Shaw

Stuart Shaw

Risk Based Quality Management Project Leader, Boehringer Ingelheim Pharmaceuticals Inc., United States

Stuart has over 20 years pharmaceutical experience within Biometrics and Data Management. He has contributed to many regulatory submissions and inspections during this time. Stuart has been working on the implementation of Risk Based Monitoring at Boehringer Ingelheim since 2013 and assumed responsibility as the global lead of this project in 2016. Stuart currently resides in Connecticut.

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.